Trial intelligence / Profile preview

Lorlatinib in ALK-positive NSCLC (China, post-ALK TKI, Phase II)

CTR20181867Phase 2Completed

Sponsor

Pfizer

Start

Oct 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1